MedTrace Logo

Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis

NCT04157322 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2025-12-03

No results posted yet for this study

Summary

Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study. Blood collection for measurements of plasma cell-free DNA hydroxymethylation signatures will be performed at different time points, before and after surgery, in order to determine if plasma hydroxymethylation signatures are more sensitive than conventional tumor markers in identifying clinically detectable recurrence at 1 year after surgery.

Conditions

  • Colorectal Cancer Stage IV
  • Colorectal Cancer Metastatic
  • Colorectal Cancer, Genetics of
  • Appendix Cancer

Interventions

DIAGNOSTIC_TEST

prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study

Blood draw

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Bruce Bissonnette, MD · University of Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2027-10-31
Completion
2027-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04157322 on ClinicalTrials.gov